Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir and Peginterferon Sequential Therapy for HBeAg+ Chronic Hepatitis B
NCT00921180Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Entecavir and peginterferon with Placebo and peginterferon (2 arms). Primary endpoint: HBeAg seroconversion rate at 76 weeks. Status: unknown.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00921180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921180.